Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases

Raylene A Reimer

Department of Biochemistry and Molecular Biology, Faculties of Kinesiology and Medicine, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4 Canada

(Requests for offprints should be addressed to R A Reimer; Email: reimer@ucalgary.ca)

Abstract

Glucagon-like peptide-1 (GLP-1) is a potent insulin secretagogue released from L-cells in the intestine. Meat hydrolysate (MH) is a powerful activator of GLP-1 secretion in the human enteroendocrine NCI-H716 cell line, but the mechanisms involved in nutrient-stimulated GLP-1 secretion are poorly understood. The objective of this study was to characterize the intracellular signalling pathways regulating MH- and amino acid-induced GLP-1 secretion. Individually, the pharmacological inhibitors, SB203580 (inhibitor of p38 mitogen-activated protein kinase (MAPK)), wortmannin (inhibitor of phosphatidylinositol 3-kinase) and U0126 (inhibitor of mitogen activated or extracellular signal-regulated protein kinase (MEK1/2) upstream of extracellular signal-regulated kinase (ERK)1/2) all inhibited MH-induced GLP-1 secretion. Further examination of the MAPK pathway showed that MH increased the phosphorylation of ERK1/2, but not p38 or c-Jun N-terminal kinase over 2–15 min. Incubation with SB203580

resulted in a decrease in phosphorylated p38 MAPK and a concomitant increase in the phosphorylation of ERK1/2. Phosphorylation of ERK1/2 was augmented by co-incubation of MH with SB203580. Inhibitors of protein kinase A and protein kinase C did not inhibit MH-induced GLP-1 secretion. In contrast to non-essential amino acids, essential amino acids (EAAs) increased GLP-1 secretion and similar to MH, activated ERK1/2. However, they also activated p38-suggesting type of protein may affect GLP-1 secretion. In conclusion, there appears to be a crosstalk between p38 and ERK1/2 MAPK in the human enteroendocrine cell with the activation of ERK1/2 common to both MH and EAA. Understanding the cellular pathways involved in nutrient-stimulated GLP-1 secretion has important implications for the design of new treatments aimed at increasing endogenous GLP-1 release in type-2 diabetes and obesity.

Journal of Endocrinology (2006) **191**, 159–170

Introduction

Glucagon-like peptide-1 (GLP-1) is a gut hormone released from intestinal L-cells in response to food ingestion (Kieffer & Habener 1999). In addition to potentiating glucose-dependent insulin secretion, GLP-1 stimulates proinsulin gene expression and biosynthesis (Drucker *et al.* 1987) and reduces food intake through interactions with the hypothalamus (Turton *et al.* 1996, Flint *et al.* 1998). The combined antidiabetic and anorectic effects of GLP-1 make it a promising new therapy for type-2 diabetes.

Previously, we identified the NCI-H716 enteroendocrine cell line as a unique human model for studying the regulation of GLP-1 secretion (Reimer *et al.* 2001). Similar to several animal cellular models, the NCI-H716 cells respond to activators of protein kinase A (PKA) and protein kinase C (PKC) with increased GLP-1 secretion (Reimer *et al.* 2001). The neuromediator, gastrin-releasing peptide, is also able to

increase GLP-1 secretion at high doses. In addition, Anini & Brubaker (2003) have described a role for M1 and M2 muscarinic receptors in the control of GLP-1 secretion in NCI-H716 cells. Reimann *et al.* (2004) have recently shown that glutamine is a potent stimulator of GLP-1 secretion from the murine glucagon gene simian virus-40 large T-antigen (GLUTag) cell line. They suggest a possible involvement of the Na-coupled glutamine transporters and using reverse transcriptase (RT)-PCR have identified several Na-coupled amino acid transporters in the GLUTag cells with the strongest bands observed for ATA-2 (electrogenic neutral amino acid transporter), ASCT-2 (sodium dependent neutral amino acid transporter type 2) and γ^+ LAT2 (electroneutral amino acid transporter; Hyde *et al.* 2003, Reimann *et al.* 2004). These transporters may play a role in the release of GLP-1 in response to protein and amino acids.

Nutrient ingestion is a major stimulus for GLP-1 release from the L-cells (Drucker 1998). The direct effect of nutrients

on GLP-1 secretion has been examined in several cellular models. Saturated fatty acids, palmitic and the unsaturated oleic acids stimulate GLP-1 secretion in human NCI-H716 cells (Reimer *et al.* 2001). In contrast, only unsaturated fatty acids were effective in the murine GLUTag enteroendocrine cell line and in fetal rat intestinal cells (Brubaker *et al.* 1998, Rocca *et al.* 2001). Meat hydrolysate (MH), previously shown in rodent cells to stimulate GLP-1 secretion (Cordier-Bussat *et al.* 1998), results in a potent stimulation of GLP-1 release in the human NCI-H716 cell line (Reimer *et al.* 2001). The cellular mechanisms by which MH induces GLP-1 secretion are not known. Given the potential use of modified diets and functional foods to enhance endogenous GLP-1 secretion and improve glucose control in human subjects, understanding the mechanisms involved in nutrient-stimulated GLP-1 secretion is critical. This *in vitro* work will help identify important targets that can ultimately be tested in future human trials.

The mitogen-activated protein kinase (MAPK) family of signalling molecules, includes extracellular signal-regulated kinase (ERK)1/2, p38 MAPK, c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), ERK3 and ERK5. MAPKs are the regulators in pathways controlling embryogenesis, cell differentiation, cell proliferation and cell death (Pearson *et al.* 2001). Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are two incretins, whose actions are mediated via their respective G-protein-coupled receptors (Brubaker & Drucker 2002). The p38 MAPK signal has been shown to mediate GLP-1 induced β -cell proliferation (Buteau *et al.* 2001) and GIP-stimulated β -(insulinoma cell line (INS)-1) cell survival (Ehses *et al.* 2003). Many other members of the vasoactive intestinal polypeptide/secretin/glucagon superfamily also exert their downstream effects via activation of MAPKs (Barrie *et al.* 1997, Montrose-Rafizadeh *et al.* 1999, Jiang *et al.* 2001). These studies demonstrate the important role played by the MAPK family of signal molecules in the physiological actions exerted by GLP-1, particularly in the pancreas. However, the role of MAPKs in the stimulation of endogenous GLP-1 secretion by nutrients has never been described. We, hereby, provide evidence for the role of MAPKs in MH-induced GLP-1 secretion in the NCI-H716 cell line. Given the lack of consensus on the role of amino acids in stimulating GLP-1 release, we also demonstrate the ability of essential amino acids (EAAs), but not non-essential amino acids (NEAAs) to trigger secretion.

Materials and Methods

Roswell Park Memorial Institute (RPMI) 1640 medium, Dulbecco's modified Eagle's medium (DMEM), L-glutamine, penicillin, streptomycin and fetal bovine serum (FBS) were from Invitrogen. BSA and MH were purchased from Sigma Chemicals, and MH was prepared as an 8% (w/v) stock solution in Krebs-Ringer bicarbonate buffer (KRB; Invitrogen) containing 0.2% BSA (w/v). The pH was

adjusted to 7.2 with NaOH, filtered through 0.2 μ m filters and aliquots stored at -20°C . The amino acid solutions (Cat. nos M5550 and M7145) were purchased from Sigma Chemicals. All phospho and total antibodies for p42/44 MAPK (ERK), p38 and JNK were purchased from New England Biolabs (Pickering, Ontario, Canada).

Cell line and culture conditions

Human NCI-H716 cells were grown in suspension at 37°C , 5% CO_2 . The culture medium was RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin. Endocrine differentiation was enhanced by growing cells in dishes coated with Matrigel (Becton Dickinson, Bedford, MA, USA), as described previously (de Bruine *et al.* 1993).

Secretion studies

Two days before the experiments, 1×10^6 cells were seeded in 12-well culture plates coated with Matrigel and containing high-glucose DMEM, 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin. On the day of the experiment, medium was replaced by KRB containing 0.2% (w/v) BSA with or without test agents and pH adjusted to 7.2. In experiments with pharmacological inhibitors, cells were preincubated with the inhibitor or dimethyl sulphoxide (DMSO) as a control for 30 min prior to the secretion period. Fresh media were added and cells incubated for 2 h at 37°C with a 2% (w/v) MH solution alone or in combination with the various inhibitors. DMSO was used as a control. Supernatants were collected with the addition of 50 $\mu\text{g}/\text{ml}$ phenylmethylsulphonyl fluoride (PMSF) and diprotin-A (34 $\mu\text{g}/\text{ml}$) and frozen at -80°C for subsequent RIA analysis. Cells were scraped off and sonicated in a homogenization buffer (1 M HCl containing 5% (v/v) HCOOH , 1% (v/v) trifluoroacetic acid and 1% (w/v) NaCl). Peptides were extracted from the cell media and homogenates using an alcohol extraction method as described by the supplier of the GLP-1(7-36) Active RIA Kit (Linco Research, Inc., St Charles, MO, USA). Protein content of the cell homogenate was determined using the Bradford protein assay (Bio-Rad, Inc.).

Western blots

Cells were lysed on ice in buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl_2 , 1 mM EGTA, 100 mM NaF and 1% NP40) containing 1 mM PMSF, 10 $\mu\text{g}/\text{ml}$ aprotinin, 10 $\mu\text{g}/\text{ml}$ leupeptin, 1 mM sodium orthovanadate and 1 mM Na_3VO_4 . Total protein concentrations were determined using the Bradford protein assay (Bio-Rad), and aliquots of each sample representing equal amounts of proteins were subjected to Western immunoblotting analysis. Cell lysates were suspended in sample buffer (10% glycerol, 62.5 mM Tris-HCl, 2% SDS and 50 mM

DTT (pH 6.8)) and subjected to electrophoresis in 10% polyacrylamide SDS gel and transferred to nitrocellulose membranes. The membranes were blocked in buffer (1× Tris-buffered saline (TBS) (50 mM Tris-base, 0.14 M NaCl, 4.8 mM KCl, 0.1% Tween-20)) with skim milk and incubated overnight with a 1:1000 dilution of antibody against phosphorylated p38, 1:5000 dilution of phosphorylated ERK1/2 antibody or 1:500 dilution of JNK antibody. Membranes were washed and incubated for 1 h with a 1:10 000 dilution of peroxidase-conjugated anti-rabbit immunoglobulin (Amersham Pharmacia). Proteins were visualized with electrochemiluminescence (ECL) substrate reagent (Amersham Pharmacia). To control for protein concentration, membranes were stripped and reprobed for total p38 kinase (1:100), total ERK1/2 (1:1000) and total JNK (1:500).

RT-PCR

RT-PCR was performed as described previously (Reimer *et al.* 2001) using the following primers: PEPT1 (SLC15A1) sense TGTCGCTCTCCATTGTCTAC, antisense TTCCACATTGTTGAACTCTGAG; Y⁺LAT2 (SLC7A6) sense GCACTCATCTACCTCATCG, antisense GATAGCAGC-CAGGACATTC; ASCT2 (SLC1A5) sense GCTTATCCG-CTTCTTCAACTCCTTC, antisense CC-ATTATTCT-CCTCCACGCACTTC; ATA-2 (SLC38A2) sense TGGTATCTGAACGGGAAGTATTTG, antisense AATTGGCACAG

CATAGACAGTC and actin sense GTTGCTATCCAGGC-TGTG, antisense CATAGTCCG-CCTAGAAGC.

Statistical analysis

Data in figures are presented as means $\pm$ S.E.M. and represent a minimum of three experiments measured in duplicate. Statistical differences were determined using the Kruskal–Wallis's *H*-test with *post hoc* analysis to determine the differences between treatments using the Mann–Whitney's *U*-test. Statistical significance was defined as $P \leq 0.05$.

Results

The total content of GLP-1 in NCI-H716 cells, as monitored by RIA, was 252.6 ± 40.7 pmol/mg protein. Basal release, during a 2 h incubation period, was $2.6 \pm 0.3\%$ ($n = 27$).

Incubation of NCI-H716 cells with SB203580, a specific inhibitor of p38 MAPK, significantly reduced MH-induced GLP-1 secretion ($291.9 \pm 46.4\%$ control) compared with MH alone ($471.0 \pm 65.2\%$ control; $P < 0.05$; Fig. 1). In addition, wortmannin, a phosphatidylinositol 3 kinase (PI3K) inhibitor, significantly reduced MH-induced GLP-1 secretion ($161.1 \pm 75.7\%$ control; $P < 0.05$) compared with MH alone ($471.0 \pm 65.2\%$ control). The U0126 compound, an inhibitor of MEK1/2 upstream from ERK1/2, also significantly reduced MH-induced GLP-1 secretion.

Figure 1 Release of glucagon-like peptide-1 (GLP-1) by NCI-H716 cells in response to treatment with various inhibitors. The treatments were: (1) medium alone (control), (2) 2% meat hydrolysate (MH), (3) 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)-pyrazolo-3,4-d-pyrimidine (PPI) (10 μ M; sarcosine related complement (Src)-family inhibitor), (4) PPI + 2% MH, (5) U0126 (5 μ M; MEK1/2 inhibitor), (6) U0126 + 2% MH, (7) SB203580 (10 μ M; p38 MAPK inhibitor), (8) SB203580 + 2% MH, (9) Wortmannin (100 nM; PI3K inhibitor), (10) Wortmannin + 2% MH. Cells were preincubated for 30 min with either medium alone or various inhibitors. Fresh medium was added containing MH with or without the inhibitors for 2 h. Secretion of GLP-1 into the medium is expressed as a percentage of the control value ($n = 5$). Results represent mean $\pm$ S.E.M. *Significant difference from control ($P \leq 0.0001$). Additionally, all treatments involving 2% MH plus an inhibitor were compared with 2% MH alone. †Significant difference between 2% MH and 2% MH in combination with an inhibitor ($P < 0.05$).

Incubation solely with wortmannin or U0126 caused a slight reduction in basal GLP-1 secretion.

In addition to the aforementioned pathways, we also investigated the role of PKC and PKA in MH-induced GLP-1 secretion. Co-incubation of MH with RpcAMPs (adenosine 3',5'-cyclic monophosphorothioate, Rp-isomer), a cAMP antagonist that blocks signal transduction of cAMP by inhibiting PKA (Dostmann *et al.* 1990) did not block MH-induced GLP-1 secretion (Fig. 2). Chelerythrine chloride, a potent, selective and cell permeable inhibitor of PKC (Jarvis *et al.* 1994) also had no effect on MH-induced GLP-1 secretion (Fig. 2). Incubation of NCI-H716 cells with one of the inhibitors alone did not alter the basal GLP-1 secretion.

Given the results of the secretory studies implicating MAPK involvement in GLP-1 secretion in response to MH, we went on to first examine the time course of the effect of MH on phosphorylation of three MAPK subfamilies. NCI-H716 cells were incubated with 2% MH followed by Western blot analysis for phosphorylated and total p38 MAPK, ERK1/2 and JNK at timed intervals. Activation of ERK1/2 MAPK was detectable and significant over 2–15 min ($P < 0.05$) and returned to basal levels by 60 min (Fig. 3). In contrast, phosphorylated levels of p38 MAPK remained unchanged. Likewise, no changes were detected in phosphorylation of JNK (data not shown). The amounts of total p38, MAPK and JNK did not change with MH over 2–60 min.

The compound, SB203580, was used to specifically inhibit p38 MAPK in the NCI-H716 cells. As expected, a significant decrease in phosphorylated levels of p38 MAPK

occurred at both 2 and 5 min (Fig. 4). Confirming results from the time course, no changes in p38 were seen with MH. The level of phosphorylated p38 that was observed after the co-incubation of SB203580 with MH did not differ from the inhibitor alone. Given the inhibition of p38 with SB203580, there appeared to be a compensatory increase in the phosphorylation of ERK1/2 MAPK, which was significant at 2 and 5 min, but greatly enhanced at the latter time point ($P > 0.05$; Fig. 5). Interestingly, co-incubation of MH with SB203580 resulted in augmented levels of phosphorylated ERK1/2.

Since MH is a complex, poorly defined protein compound, we also wanted to investigate the effects of well-defined essential and NEAA mixtures on GLP-1 secretion and MAPK activation in the NCI-H716 cell line. The EAAs dose-dependently increased GLP-1 secretion with release reaching significance at the highest concentration tested (6.9 g/l; Fig. 6). NEAAs, however, were not able to trigger GLP-1 release above the baseline control levels. In a separate experiment, we compared GLP-1 secretion under the conditions of equivalent nitrogen content with 2% MH and EAAs and NEAAs as well as two additional treatments, which controlled for differences in the pH of the solutions, namely pH 7.3 and 9.5. Both MH and EAAs significantly increased GLP-1 secretion ($P < 0.05$), but the increase was greater for MH. NEAAs and changes in pH alone did not affect GLP-1 secretion (Fig. 6).

Similar to the GLUtag cell line (Reimann *et al.* 2004), we now confirm the presence of the ATA-2, ASCT-2 and y^+ LAT2 in human NCI-H716 cells (Fig. 7). MH is a

Figure 2 Effect of protein kinase (PKA) and protein kinase C (PKC) inhibitors on meat hydrolysate (MH)-induced glucagon-like peptide-1 (GLP-1) release. Secretion of GLP-1 by NCI-H716 cells is shown in response to treatment with medium alone (control), MH (2%), RpcAMPs (10 μ M, PKA inhibitor) and chelerythrine (2 μ M, PKC inhibitor) alone or in combination with MH ($n=3$). Cells were preincubated for 30 min with either medium alone or various inhibitors. Fresh medium was added containing MH with or without the inhibitors for 2 h. Secretion of GLP-1 into the medium is expressed as a percentage of the control value. Results represent mean $\pm$ S.E.M. *Significant difference between control and 2% MH ($P \leq 0.001$). No significant differences were detected with the other treatments.

Figure 3 Activation of extracellular signal-related kinase (ERK)1/2 but not p38 MAPK by MH. Western blots were performed with the phosphospecific and non-phosphorylated form of ERK1/2 and p38 MAPK antibodies ($n=3$). Ratios of phosphorylated:non-phosphorylated signals were calculated and normalized to control. (A) *Significant difference from baseline control ($P<0.05$). No significant differences were seen in p38 across time. (B) Representative Western blots shown with lane assignments as follows: C, control; 2, 2 min; 5, 5 min; 15, 15 min; 60, 60 min with 2% MH.

complex mixture of smaller peptides and we, therefore, also examined the H^+ -driven di- and tri-peptide transporter PEPT1, but could not detect expression of this transporter in our cells.

To complete our examination of the effect of amino acids on intracellular pathways, we again performed time-course experiments for EAAs and NEAAs on phosphorylated and total ERK1/2 and p38. In equivalent doses, both EAAs and MH significantly increased phosphorylated ERK1/2 ($P<0.05$), whereas NEAA had no effect (Fig. 8). In contrast to findings with MH, the EAAs were also able to significantly

increase the levels of phosphorylated p38 at 2, 5, 15 and 60 min (Fig. 9). The NEAA and MH had no effect on phosphorylated p38 levels (Fig. 9).

Given the activation of ERK1/2 seen with both MH and EAA, we performed an initial screen for other agonists that potentially stimulate GLP-1 secretion via activation of this MAPK pathway. While epidermal growth factor (100 ng/ml), fibroblast growth factor (100 ng/ml) and insulin (100 ng/ml) all elicit robust activation of ERK1/2 in our NCI-H716 cells, they were unable to trigger GLP-1 secretion at concentrations of either 100 or 300 ng/ml over 2 h (data

Figure 4 Abundance of phosphorylated p38 MAPK following incubation with MH and/or SB203580 inhibitor. Western blots were performed with the phosphospecific and non-phosphorylated form of the p38 MAPK antibody ($n=3$). Ratios of phosphorylated:non-phosphorylated p38 MAPK signals were calculated and normalized to control.

(A) Treatments with different letters are significantly different from each other within the 2 or 5 min time point ($P<0.05$). For example, the relevant comparison of MH versus SB + MH at 2 min is significantly different. (B) Representative Western blots of phosphorylated and total p38 MAPK. Lanes 1–4, 2 min; lanes 5–8, 5 min; lanes 1 and 5, control; lanes 2 and 6, SB203580; lanes 3 and 7, 2% MH; lanes 4 and 8, SB203580 + 2% MH.

not shown). As a negative control, lysophosphatidic acid (10 μ m), which did not activate ERK1/2 in the NCI-H716 cells did not trigger GLP-1 release. Other compounds tested, including endothelin-1, stromal cell-derived factor-1, platelet-derived growth factor, tumour necrosis factor α , granulocyte-macrophage colony-stimulating factor and lipopolysaccharide did not elicit an activation of ERK1/2 in the NCI-H716 cells (data not shown). Given that activation of ERK1/2 alone is not sufficient to induce GLP-1 secretion, it may suggest that MH is able to initiate GLP-1 secretion and perhaps then potentiate its release via the ERK1/2 pathway. This will require further examination.

Discussion

MH is a potent stimulator of GLP-1 secretion in human NCI-H716 (Reimer *et al.* 2001) and murine enteroendocrine GLUTag (Cordier-Bussat *et al.* 1998) cell lines. Although

some controversy remains regarding the effectiveness of protein on triggering GLP-1 secretion from the L-cell (Xiao *et al.* 1999), Reimann *et al.* (2004) have recently demonstrated that glutamine, at a concentration similar to normal plasma glutamine levels is able to potently stimulate GLP-1 from murine GLUTag cells. They demonstrate a role for membrane depolarization and increased intracellular calcium in enhancing GLP-1 secretion (Reimann *et al.* 2004). Results from our present study confirm the ability of a protein hydrolysate derived from meat, as well as a mixture of EAAs to potently stimulate GLP-1 secretion from NCI-H716 cells and demonstrate the involvement of ERK1/2 and p38 MAPK in this secretion.

In addition to the MAPK family, we also determined that the inhibition of PI3K impaired MH-induced GLP-1 secretion. In fact, both p38 MAPK and PI3K have been implicated in the growth promotive effects of GLP-1 (Buteau *et al.* 1999, 2001). It is, therefore, not unusual that several signalling modules are involved in the cellular

Figure 5 Abundance of phosphorylated ERK1/2 MAPK following incubation with MH and/or SB203580 inhibitor. Western blots were performed with the phosphospecific and non-phosphorylated form of the ERK1/2 MAPK antibody ($n=3$). Ratios of phosphorylated:non-phosphorylated ERK1/2 MAPK signals were calculated and normalized to control. (A) Treatments with different letters are significantly different from each other within the 2 or 5 min time point ($P<0.05$). (B) Representative western blot. Lanes 1–4, 2 min; lanes 5–8, 5 min; lanes 1 and 5, control; lanes 2 and 6, SB203580; lanes 3 and 7, 2% MH; lanes 4 and 8, SB203580 + 2% MH.

response to MH. While glucose is known to cause a rapid and continuous activation of ERK1/2 in β -cells (Arnette *et al.* 2003), our study is the first to describe the activation of ERK1/2 by MH and furthermore by EAAs in enteroendocrine cells.

Our work is in agreement with recently published evidence that enhanced secretion of GLP-1 by free fatty acids (FFA) in the murine cholecystokinin-secreting murine small intestine endocrine (STC)-1 cell line is accompanied by the activation of ERK1/2 (Hirasawa *et al.* 2005). GPR120, a G-protein-coupled receptor abundantly expressed in the STC-1 cell line, was identified as a receptor for unsaturated long-chain FFA. Transfection of the STC-1 cells with GPR-120-specific small interfering RNA significantly reduced α -linolenic acid-induced GLP-1 secretion (Hirasawa *et al.* 2005). Transfection of NCI-H716 cells (which have little expression of GPR120) with GPR120 improved the ability of NCI-H716 cells to secrete GLP-1 in response to α -linolenic acid (Hirasawa *et al.* 2005). Taken

together with our present work, it suggests that ERK1/2 may serve as a common pathway regulating nutrient-induced GLP-1 secretion.

We and other researchers had previously shown that activation of the PKA and PKC pathways in enteroendocrine cells stimulates GLP-1 secretion (Brubaker & Vranic 1987, Buchan *et al.* 1987, Drucker *et al.* 1987, Reimer *et al.* 2001). In the present study, however, we found that inhibition of the PKA or PKC pathway with RpcAMPS or chelerythrine respectively, did not reduce MH-induced GLP-1 secretion. These findings are in agreement with work by Reimann *et al.* (2004) in which inhibition of PKA or PKC did not affect glutamine-stimulated GLP-1 secretion. The intracellular amino acid target mammalian target of rapamycin mTOR also did not significantly impair the response to glutamine (Reimann *et al.* 2004). Inhibition of calmodulin kinase impaired GLP-1 secretion in response to glutamine but also glucose and alanine. In contrast to the lack of effects of PKA and PKC inhibitors, blocking p38 MAPK, PI3K or MEK1/2,

Figure 6 Effect of essential and non-essential amino acids (NEAAs) on GLP-1 secretion. (A) Cells were incubated for 2 h with increasing concentrations of a mixture of essential amino acids (EAA; MEM, Sigma no. 5550) or a mixture of NEAAs (Sigma no. 7145; $n=3$). The concentrations displayed for both EAA and NEAA equate to 1=0.69 g/l, 2=3.47 g/l and 3=6.90 g/l. *EAA 3 is significantly different from all other treatments ($P<0.05$). (B) Cells were incubated for 2 h with equal concentrations (matched for nitrogen content) of MH, EAA or NEAA or two control solutions differing in pH alone ($n=3$). *Secretion of GLP-1 with MH and EAA was significantly greater than control or NEAA treatments ($P<0.05$). No effect of pH was seen on GLP-1 secretion.

all resulted in a reduction in the potential for MH to trigger GLP-1 release. Our specific examination of the MAPK pathways suggests that the ERK1/2 and p38 MAPK subfamilies appear to work in concert to regulate the response to MH by the enteroendocrine cell. This is based on the observations that MH increases ERK1/2 phosphorylation and that inhibition of p38 MAPK further augments the level of phosphorylated ERK1/2 in response to MH. This same crosstalk between ERK1/2 and p38 MAPK has been observed in the rat pineal gland in response to norepinephrine (Mackova *et al.* 2000) and in a rat hepatoma cell line (Singh *et al.* 1999).

The work by Reimann & Gribble (2002) also suggests that GLUTag cells are electrically active and respond to increased glucose concentrations with membrane depolarization, triggering enhanced action potential firing and GLP-1 secretion. Interestingly, the non-metabolizable sugar,

methyl- α -glucopyranoside, also stimulates electrical activity and GLP-1 secretion by inducing an inward current, largely explained by electrogenic actions of sodium-glucose co-transporters (Gribble *et al.* 2003). Glutamine has also been shown, by the same group, to both initiate GLP-1 secretion in the GLUTag cell line via triggering membrane depolarization and generating action potentials, as well as potentiating GLP-1 secretion downstream of the calcium signal (Reimann *et al.* 2004). Although to date, work elucidating the mechanisms by which nutrients stimulate GLP-1 release has been limited, recent studies coupled with our data suggest that the pathways involved are likely complex and in some cases nutrient specific.

MH is a complex compound that is poorly defined, but it is likely to be composed of a mixture of di- and tri-peptides and amino acids. It was, therefore, our intent to provide further insight into the active components of this protein source that

Figure 7 Expression of amino acid and peptide transporters in NCI-H716 cells. Total RNAs were reverse transcribed and amplified by PCR ($n=3$). The lanes represent M, Marker; C, negative control; 1, oligopeptide transporter PEPT1; 2, Na^+ -dependent amino acid transporter $\text{Y}^+\text{LAT}2$; 3, Na^+ -dependent neutral amino acid transporter ASCT2; 4, Na^+ -dependent neutral amino acid transporter ATA-2. The intense band on the marker represents a size of 600 bp. Predicted band sizes are 318, 333, 345 and 327 bp respectively and 739 bp for the internal standard of actin.

stimulate GLP-1 secretion. We effectively demonstrated that a mixture of EAAs, in contrast to a mixture of NEAAs, stimulates GLP-1 secretion in human NCI-H716 cells. While our cells did not express the H^+ -coupled peptide transporter 1 (PEPT1), which mediates transport of small peptides from the lumen into cells (Terada & Inui 2004), we did confirm the presence of several of the same amino acid transporters (ATA-2, ASCT-2 and $\text{y}^+\text{LAT}2$) reported by Reimann *et al.* (2004) in the murine GLUTag cells. ATA-2 is an electrogenic amino acid transporter and evidence from Reimann *et al.* (2004) demonstrates that the depolarizing action of glutamine contributes to GLP-1 secretion. The role of depolarization by MH or a mixture of EAAs remains to be demonstrated in human NCI-H716 cells.

Since the evidence for the role of proteins and amino acids in GLP-1 secretion has been conflicting; it is important to

Figure 8 Activation of ERK1/2 by essential but not NEAAs. Western blots were performed with the phosphospecific and non-phosphorylated form of ERK1/2 antibodies ($n=3$). Ratios of phosphorylated:non-phosphorylated ERK1/2 signals were calculated and normalized to control. (A) At 5 min, there was a significant ($P<0.05$) increase in ERK1/2 phosphorylation with EAA compared with control and all other time points for EAA and NEAA. *For comparison, MH also significantly increased ERK1/2 phosphorylation at 5 min. (B) Representative Western blots shown with lane assignments as follows: C, control; 2, 2 min; 5, 5 min; 15, 15 min; 60, 60 min; MH, 2% MH at 5 min.

Figure 9 Abundance of p38 following incubation with essential and NEAAs. Western blots were performed with the phosphospecific and non-phosphorylated form of p38 antibodies ($n=3$). Ratios of phosphorylated:non-phosphorylated p38 signals were calculated and normalized to control. (A) *Significant activation of p38 following incubation with EAA at 2, 5, 15 and 60 min ($P<0.05$). (B) Representative Western blots shown with lane assignments as follows: C, control; 2, 2 min; 5, 5 min; 15, 15 min; 60, 60 min; MH, 2% MH at 5 min.

continue to probe the cellular mechanisms responsible for endogenous secretion. While some show that oral amino acids, but not luminal perfusion induce a rapid plasma GLP-1 response (Herrmann *et al.* 1995), others show that an oral protein meal (Elliott *et al.* 1993) but not ileal protein perfusion (Layzer *et al.* 1995) result in elevated plasma GLP-1 levels. While confusing, some explanation may be found in the type of protein utilized based on the findings of Hall *et al.* (2003), who showed that plasma GLP-1 is higher following a whey preload compared with casein. Whey is considered a 'fast' protein, whereas casein is considered a 'slow' protein based on their differences in rate of digestion and absorption (Boirie *et al.* 1997). In addition to the speed with which dietary amino

acids are delivered to the plasma (Boirie *et al.* 1997), whey also contains a high proportion of branched chain amino acids (Ha & Zemel 2003), which are EAAs and may affect GLP-1 secretion. Our results suggest that EAAs can exert a direct stimulatory effect on GLP-1 secretion in the human NCI-H716 cell line. Even though many proteins are absorbed by the time they reach the distal small intestine, it is nevertheless important to understand the mechanisms by which various protein sources, including MH, stimulate GLP-1 secretion. The rapid advances in the area of functional foods have the potential to foster the development of novel foods with specific targeted actions, including GLP-1 release from the distal gut.

In conclusion, we have demonstrated the involvement of ERK1/2 MAPK in the secretion of GLP-1 in response to MH. When a mixture of EAAs was used to give greater definition to the complex hydrolysate, p38 MAPK was activated in addition to ERK1/2. This work provides evidence for the cellular pathways involved in nutrient-stimulated GLP-1 release. While our work suggests that protein hydrolysates and mixtures of EAAs are effective potentiators of GLP-1 secretion, work by other researchers suggests that even single amino acids such as glutamine may be an effective nutrient stimulus (Reimann *et al.* 2004). Evaluating these compounds *in vivo* will shed light on the potential for their use in patients perhaps in the form of functional foods. Identification of cellular targets and mechanisms involved in GLP-1 release using this *in vitro* model will provide important insight for the design of future human trials with the ultimate goal of designing novel nutritional strategies for the treatment of type-2 diabetes and obesity.

Acknowledgements

The author would like to thank Kristine Lee for her extensive technical help and Dr S Robbins for his help with the MAPK inhibitors and Western blots. This work was supported in part by the Canadian Institutes for Health Research, Natural Sciences and Engineering Research Council and the Canadian Foundation for Innovation. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References

Anini Y & Brubaker PL 2003 Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L-cells. *Endocrinology* **144** 3244–3250.

Arnette D, Beers Gibson T, Lawrence MC, January B, Khoo S, McGlynn K, Vanderbilt CA & Cobb MH 2003 Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic B-cells. *Journal of Biological Chemistry* **278** 32517–32525.

Barrie AP, Clohessy AM, Buensuceso CS, Rogers MV & Allen JM 1997 Pituitary adenyl cyclase-activating peptide stimulates extracellular signal-regulated kinase 1 or 2 (ERK1/2) activity in a Ras-independent, mitogen-activated protein kinase/ERK kinase 1 or 2-dependent manner in PC-12 cells. *Journal of Biological Chemistry* **272** 19666–19671.

Boirie Y, Dangin M, Gachon P, Vasson M, Maubois J & Beaufrère B 1997 Slow and fast dietary proteins differently modulate postprandial protein accretion. *PNAS* **94** 14930–14935.

Brubaker PL & Drucker D 2002 Structure–function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1 and GLP-2 receptors. *Receptors and Channels* **8** 179–188.

Brubaker PL & Vranic M 1987 Fetal rat intestinal cells in monolayer culture: a new *in vitro* system to study the glucagon-like immunoreactive peptides. *Endocrinology* **120** 1976–1985.

Brubaker PL, Schloos J & Drucker DJ 1998 Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. *Endocrinology* **139** 4108–4114.

de Bruine AP, Dinjens WN, van der Linden EP, Pijs MM, Moerkerk PT & Bosman FT 1993 Extracellular matrix components induce endocrine differentiation *in vitro* in NCI-H716 cells. *American Journal of Pathology* **142** 773–782.

Buchan AM, Barber DL, Gregor M & Soll AH 1987 Morphologic and physiologic studies of canine ileal enteroglucagon-containing cells in short-term culture. *Gastroenterology* **93** 791–800.

Buteau J, Roduit R, Susini S & Prentki M 1999 Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity. *Diabetologia* **42** 856–864.

Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ & Prentki M 2001 Protein kinase C gamma activation mediates glucagon-like peptide-1-induced pancreatic B-cell proliferation. *Diabetes* **50** 2237–2243.

Cordier-Bussat M, Bernard C, Levenez F, Klages N, Laser-Ritz B, Philippe J, Chayvialle JA & Cuber JC 1998 Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide-1 and the transcription of the proglucagon gene. *Diabetes* **47** 1038–1045.

Dostmann WR, Taylor SS, Genieser HG, Jastorff B, Doskeland SO & Oegreid D 1990 Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3',5'-cyclic phosphorothioates. *Journal of Biological Chemistry* **265** 10484–10491.

Drucker DJ 1998 Glucagon-like peptides. *Diabetes* **47** 159–169.

Drucker DJ, Philippe J, Mojsov S, Chick WL & Habener JF 1987 Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. *PNAS* **84** 3434–3438.

Ehlers JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth H-U, Pederson RA & McIntosh CH 2003 Glucose-dependent insulinotropic polypeptide promotes B-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. *Endocrinology* **144** 4433–4445.

Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J & Marks V 1993 Glucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24 h secretion patterns. *Journal of Endocrinology* **138** 159–166.

Flint A, Raben A, Astrup A & Holst JJ 1998 Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. *Journal of Clinical Investigation* **101** 515–520.

Gribble FM, Williams L, Simpson AK & Reimann F 2003 A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. *Diabetes* **52** 1147–1154.

Ha E & Zemel MB 2003 Functional properties of whey, whey components, and essential amino acids: mechanisms underlying health benefits for active people (review). *Journal of Nutritional Biochemistry* **14** 251–258.

Hall WL, Millward DJ, Long SJ & Morgan LM 2003 Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. *British Journal of Nutrition* **89** 239–248.

Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R & Goke B 1995 Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. *Digestion* **56** 117–126.

Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S & Tsujimoto G 2005 Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. *Nature Medicine* **11** 90–94.

Hyde R, Taylor PM & Hundal HS 2003 Amino acid transporters: roles in amino acid sensing and signalling in animal cells. *Biochemical Journal* **373** 1–18.

Jarvis WD, Turner AJ, Povirk LF, Traylor RS & Grant S 1994 Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. *Cancer Research* **54** 1707–1714.

Jiang Y, Cypress AM, Muse ED, Wu C-R, Unson CG, Merrifield RB & Sakmar TP 2001 Glucagon receptor activates extracellular signal-regulated protein kinase 1/2 via cAMP-dependent protein kinase. *PNAS* **98** 10102–10107.

Kieffer TJ & Habener JF 1999 The glucagon-like peptides. *Endocrine Reviews* **20** 876–913.

- Layer P, Holst JJ, Grandt D & Goebell H 1995 Ileal release of glucagon-like peptide-1 (GLP-1): association with inhibition of gastric acid secretion in humans. *Digestive Diseases and Sciences* **40** 1074–1082.
- Mackova M, Man JR, Chik CL & Ho AK 2000 p38^{MAPK} inhibition enhances basal and norepinephrine stimulated p42/44^{MAPK} phosphorylation in rat pinealocytes. *Endocrinology* **141** 4202–4208.
- Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W & Bernier M 1999 Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. *Endocrinology* **140** 1132–1140.
- Pearson G, Robinson F, Beers Gibson T, Xu B-E, Karandikar M, Berman K & Cobb MH 2001 Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocrine Reviews* **22** 153–183.
- Reimann F & Gribble FM 2002 Glucose-sensing in glucagon-like peptide-1 secreting cells. *Diabetes* **51** 2757–2763.
- Reimann F, Williams L, da Silva Xavier G, Rutter GA & Gribble FM 2004 Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. *Diabetologia* **47** 1592–1601.
- Reimer RA, Darimont C, Nicolas-Metral V, Gremlich S, Rüegg UT & Macé K 2001 A human cellular model for studying the regulation of glucagon-like peptide 1 secretion. *Endocrinology* **142** 4522–4528.
- Rocca AS, LaGreca J, Kalitsky J & Brubaker PL 2001 Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. *Endocrinology* **142** 1148–1155.
- Singh RP, Dhawan P, Golden C, Kapoor GS & Mehta KD 1999 One-way cross-talk between p38^{MAPK} and p42/44^{MAPK}. Inhibition of p38^{MAPK} induces low density lipoprotein receptor expression through activation of the p42/44^{MAPK} cascade. *Journal of Biological Chemistry* **274** 19593–19600.
- Terada T & Inui K 2004 Peptide transporters: structure, function, regulation and application for drug delivery. *Current Drug Metabolism* **5** 85–94.
- Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD *et al.* 1996 A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature* **379** 69–72.
- Xiao Q, Boushey RP, Drucker DJ & Brubaker PL 1999 Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. *Gastroenterology* **117** 99–105.

Received in final form 13 June 2006

Accepted 29 June 2006

Made available online as an Accepted Preprint

17 July 2006